JP2013532692A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532692A5
JP2013532692A5 JP2013522013A JP2013522013A JP2013532692A5 JP 2013532692 A5 JP2013532692 A5 JP 2013532692A5 JP 2013522013 A JP2013522013 A JP 2013522013A JP 2013522013 A JP2013522013 A JP 2013522013A JP 2013532692 A5 JP2013532692 A5 JP 2013532692A5
Authority
JP
Japan
Prior art keywords
alkyl
carbonyl
piperidin
piperidine
picolinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013522013A
Other languages
English (en)
Japanese (ja)
Other versions
JP5889895B2 (ja
JP2013532692A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046019 external-priority patent/WO2012016217A1/en
Publication of JP2013532692A publication Critical patent/JP2013532692A/ja
Publication of JP2013532692A5 publication Critical patent/JP2013532692A5/ja
Application granted granted Critical
Publication of JP5889895B2 publication Critical patent/JP5889895B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013522013A 2010-07-29 2011-07-29 Ampk活性化複素環化合物およびその使用方法 Expired - Fee Related JP5889895B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36892810P 2010-07-29 2010-07-29
US61/368,928 2010-07-29
PCT/US2011/046019 WO2012016217A1 (en) 2010-07-29 2011-07-29 Ampk-activating heterocyclic compounds and methods for using the same

Publications (3)

Publication Number Publication Date
JP2013532692A JP2013532692A (ja) 2013-08-19
JP2013532692A5 true JP2013532692A5 (https=) 2014-09-04
JP5889895B2 JP5889895B2 (ja) 2016-03-22

Family

ID=44504240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013522013A Expired - Fee Related JP5889895B2 (ja) 2010-07-29 2011-07-29 Ampk活性化複素環化合物およびその使用方法

Country Status (24)

Country Link
US (8) US8791136B2 (https=)
EP (1) EP2598483B1 (https=)
JP (1) JP5889895B2 (https=)
KR (1) KR101764952B1 (https=)
CN (1) CN103201267B (https=)
AU (1) AU2011283684B2 (https=)
BR (1) BR112013002112B1 (https=)
CA (1) CA2806341C (https=)
CL (1) CL2013000261A1 (https=)
DK (1) DK2598483T3 (https=)
EA (1) EA025611B1 (https=)
ES (1) ES2823350T3 (https=)
HU (1) HUE052110T2 (https=)
IL (1) IL223856A (https=)
MX (1) MX338707B (https=)
MY (1) MY165584A (https=)
NZ (1) NZ605692A (https=)
PE (1) PE20130774A1 (https=)
PL (1) PL2598483T3 (https=)
PT (1) PT2598483T (https=)
SG (1) SG186850A1 (https=)
UA (1) UA112061C2 (https=)
WO (1) WO2012016217A1 (https=)
ZA (2) ZA201300374B (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079078A1 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Diamine derivatives as inhibitors of leukotriene a4 hydrolase
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
PL2763979T3 (pl) 2011-10-07 2019-06-28 Takeda Pharmaceutical Company Limited Związki 1-arylokarbonyl-4-oksy-piperydynowe użyteczne do leczenia chorób neurodegeneracyjnych
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
MX2015011677A (es) * 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
EA028545B1 (ru) * 2013-06-10 2017-11-30 Астеллас Фарма Инк. Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20160214967A1 (en) * 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6523303B2 (ja) 2014-01-17 2019-05-29 ノバルティス アーゲー Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015131773A1 (zh) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
EA031866B1 (ru) * 2014-06-06 2019-03-29 Астеллас Фарма Инк. Производное 2-ациламинотиазола или его соль
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
BR112017003901A2 (pt) 2014-08-26 2017-12-12 Astellas Pharma Inc derivado de 2-aminotiazola ou sal do mesmo
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Fgfr4阻害剤としての縮環二環式ピリジル誘導体の使用
BR112017005104B1 (pt) 2014-10-10 2022-08-23 Pulmocide Limited Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos
KR20200087273A (ko) 2014-10-24 2020-07-20 란도스 바이오파마, 인크. 란티오닌 합성효소 c-유사 2-계 치료제
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
ES2775449T3 (es) 2016-01-22 2020-07-27 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina sustituida como inhibidores de nik
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
BR112019019109B1 (pt) * 2017-03-15 2023-11-07 Lunella Biotech, Inc Compostos mitorriboscina, composição farmacêutica compreendendo os mesmos, e seus usos direcionados para células cancerosas, bactérias e levedura patogênica
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
SG10202011632RA (en) 2017-10-27 2021-01-28 Boehringer Ingelheim Int Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
JP7542538B2 (ja) 2018-09-18 2024-08-30 ニカング セラピューティクス, インコーポレイテッド Srcホモロジー-2ホスファターゼ阻害剤としての縮合三環式環誘導体
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021008995A2 (pt) 2018-12-26 2021-08-10 Raqualia Pharma Inc. derivados heterocíclicos como bloqueadores de nav1.7 e nav1.8
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7551629B2 (ja) 2019-02-05 2024-09-17 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
MX2021013531A (es) 2019-05-05 2022-02-11 Qilu Regor Therapeutics Inc Inhibidores de cdk.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
BR112022002387A2 (pt) 2019-12-20 2022-09-06 Landos Biopharma Inc Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CA3188340A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
CA3195702A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2024006297A1 (en) * 2022-06-28 2024-01-04 Modulation Therapeutics, Inc. Scd1 inhibitors for treating liver disease
WO2025018978A1 (en) * 2023-07-14 2025-01-23 Modulation Therapeutics, Inc. Scd1 inhibitors for treating hematolymphoid neoplasms
WO2025217513A1 (en) * 2024-04-11 2025-10-16 The Trustees Of Indiana University Activation of plcg2 as a therapeutic strategy for the treatment of alzheimer's disease
CN119039234A (zh) * 2024-08-19 2024-11-29 中国药科大学 一种哒嗪酰胺类化合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014571A1 (en) 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
WO2007098086A2 (en) 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
DE602006021591D1 (de) * 2006-12-11 2011-06-09 Genetics Co Inc Aromatische 1,4-DI-Carboxylamide und deren Verwendung
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CA2697077C (en) * 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
BRPI0820171B8 (pt) * 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
MX2010011288A (es) * 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
CN102365275B (zh) * 2009-01-28 2014-09-24 里格尔药品股份有限公司 羧酰胺化合物及其使用方法
AU2010241742A1 (en) * 2009-04-27 2011-11-17 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
US9409884B2 (en) * 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them

Similar Documents

Publication Publication Date Title
JP2013532692A5 (https=)
CN117242067B (zh) 作为glp1r激动剂的新型芳醚取代杂环类化合物
JP5889895B2 (ja) Ampk活性化複素環化合物およびその使用方法
JP5432718B2 (ja) ピロール化合物
EP3101015B1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
JP4035559B1 (ja) 酸分泌抑制薬としての1−ヘテロシクリルスルホニル、2−アミノメチル、5−(ヘテロ−)アリール置換1−h−ピロール誘導体
US20130029962A1 (en) Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
JP2011506480A5 (https=)
JP2011503210A5 (https=)
JP2010514788A5 (https=)
KR20260042557A (ko) 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
US20130029961A1 (en) Substituted Heterocyclic Aza Compounds
JP2008516902A5 (https=)
JP2008509955A5 (https=)
JP2012516349A5 (https=)
CN103153957B (zh) N-吡啶-3-基或n-吡嗪-2-基甲酰胺类
EP2448584B1 (en) Substituted 4-hydroxypyrimidine-5-carboxamides
EA052585B1 (ru) Новые гетероциклические соединения, замещенные простым ариловым эфиром, в качестве агонистов glp1r
WO2025222008A1 (en) Glucagon receptor agonists and their use as therapies
JP2007516290A5 (https=)
RU2376295C2 (ru) Производные пиримидинона и фармацевтическая композиция на их основе, обладающая свойствами ингибитора нейтрофильной эластазы человека
TW201311664A (zh) 以含被取代吡唑芳環之羧醯胺與尿素衍生物做為類香草素受體之配位體